AstraZeneca

AstraZeneca to expand its Maryland biologics manufacturing center, add 300 jobs

Monday, November 24, 2014 02:44 PM

AstraZeneca plans to expand its biologics manufacturing center in Frederick, Md. The more than $200 million project will increase production capacity at the facility to support AZ’s maturing pipeline, and will help the company keep pace with a growing demand for the development and use of biologics, which currently represent nearly 50% of AZ’s overall pipeline.

More... »


AstraZeneca, Manchester University form Advanced Drug Delivery Center

Thursday, November 6, 2014 12:31 PM

The University of Manchester and AstraZeneca have entered into a strategic collaboration to develop cutting-edge technologies designed to enhance the way drugs work and deliver better health outcomes for patients. Together, they are launching the North West Center for Advanced Drug Delivery, which will be housed in Manchester Pharmacy School and will have links into a wide range of research groups throughout the university.

More... »


MedImmune acquires Definiens, strengthens immuno-oncology capabilities

Wednesday, November 5, 2014 12:55 PM

AstraZeneca’s global biologics R&D arm MedImmune has entered into an agreement to acquire Germany-based Definiens, a privately held company focused on imaging and data analysis technology, known as Tissue Phenomics, which dramatically improves the identification of biomarkers in tumor tissue.

More... »

AstraZeneca has acquired Almirall’s respiratory business

Wednesday, November 5, 2014 12:45 PM

Almirall, a global company based in Barcelona dedicated to providing valuable medicines through its R&D, agreements and alliances, has completed the transaction to transfer to AstraZeneca the rights to Almirall's respiratory franchise after all closing conditions have been satisfied. AZ now will own the rights for the development and commercialization of Almirall's existing proprietary respiratory business, including rights to revenues from Almirall's partnerships, as well as its pipeline of investigational novel therapies.

More... »

AstraZeneca, Pharmacyclics, Janssen partner

Wednesday, November 5, 2014 12:37 PM

AstraZenecaPharmacyclics and Janssen R&D have entered into a clinical trial collaboration to evaluate the efficacy and safety of AstraZeneca's investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, in combination with imbruvica (ibrutinib), an oral Bruton's tyrosine kinase inhibitor, co-developed and co-commercialized by Pharmacyclics and Janssen Biotech. The study will assess the combination as a treatment for patients with hematologic cancers including diffuse large B-cell lymphoma and follicular lymphoma, which are investigational uses for both compounds.

More... »

Sanofi board ousts CEO Viehbacher

Thursday, October 30, 2014 08:46 AM

Paris-based biopharmaceutical company Sanofi ousted CEO Chris Viehbacher Wednesday, just two days after reporting disappointing quarterly earnings.

More... »

PharmaTimes launches 2015 Clinical Researcher of the Year competition

Wednesday, October 29, 2014 08:21 AM

The 2015 PharmaTimes Clinical Researcher of the Year-The Americas competition is open for entry. All research professionals are encouraged to enter.

More... »

Cancer Innovation forum calls for improving cancer research ecosystem

Monday, October 27, 2014 12:58 PM

Accelerating the delivery of promising new cancer treatments depends on one critical requirement—ensuring patients are actively involved in the cancer research and drug development process from beginning to end.

More... »

Treasury’s tax inversion changes scuttle some big biopharma mergers, modify others, prompting calls for Congressional corporate tax reform

Thursday, October 23, 2014 03:50 PM

The widely-discussed $54.6 billion acquisition of Dublin-based Shire by AbbVie is officially canceled, having crumbled after a notice by the U.S. Treasury Department to tighten tax rules that deter U.S. companies from moving their legal headquarters to countries with lower business taxes.

More... »

ProNAi Therapeutics adds five to senior management team

Thursday, October 23, 2014 03:17 PM

ProNAi Therapeutics, a private company dedicated to developing and commercializing a new class of therapies based on its proprietary DNAi platform, has added five seasoned executives to its senior management team.

More... »


CWWeekly

July 27

AB Science warned about putting study volunteers in danger

FDA, Google unite to detect search-data adverse events

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

July

Integrated research partnerships build momentum
Research function provides infrastructure, leverages large pool of health systems' patients and data

'Right to Try' laws challenge clinical trial process
20 states pass, 20 more pending allowing access to study drugs without FDA and IRB approval

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

June

TransCelerate Biopharma turns three
High-profile consortium has made inroads fixing wasteful practices, but it still has more work ahead

Pharma industry improves its tarnished reputation
Delivering innovation, social responsibility will help rebuild trust

Already a subscriber?
Log in to your digital subscription.

Purchase the June issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs